This site is intended for health professionals only
Friday 22 June 2018
Share |

Xarelto® approved for the treatment of PE and DVT

Bayer HealthCare's oral anticoagulant Xarelto® (rivaroxaban) has been approved by the European Commission (EC) for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep vein thrombosis (DVT) and PE in adults. This approval makes rivaroxaban the only novel oral anticoagulant approved in this indication in the EU. 

Ads by Google